Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of LVRNA021 Bivalent mRNA Vaccine Booster in Adults
NCT05939596Phase 1Active, not recruiting
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing LVRNA021 with Placebo (2 arms). Primary endpoint: Incidence of solicited and unsolicited adverse events. Started Aug 2023; status: active, not recruiting.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05939596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939596.